How Glitazone Drugs Work and Why Their Use Is Limited

Glitazones, formally known as thiazolidinediones or TZDs, are a class of diabetes drugs that work by making the body more sensitive to insulin. Pioglitazone is the only member still widely prescribed, though at one point three different glitazones were on the market. The class has had one of the most dramatic arcs in modern pharmacology: initially celebrated as a fundamentally new approach to treating type 2 diabetes, then battered by safety scandals involving liver failure, heart attacks, and cancer fears, and now quietly finding renewed relevance for conditions well beyond blood sugar control.

How Glitazones Work

Glitazones target a receptor inside cells called PPARγ (peroxisome proliferator-activated receptor gamma). When the drug binds to this receptor, it acts as a kind of master switch for gene activity, turning on genes involved in how the body processes fat and sugar.¹ PPARγ is most active in fat tissue, so most of the drug’s initial action happens in fat cells. But the downstream effects ripple outward to the liver, muscles, and even the pancreas.

The core problem in type 2 diabetes is insulin resistance: the body produces insulin, but cells don’t respond to it properly. Glitazones attack this problem at its root rather than simply forcing the pancreas to produce more insulin (as some older drugs do) or blocking sugar absorption. They reduce insulin resistance across fat tissue, muscle, and the liver simultaneously.² In fat tissue, the drugs suppress the release of free fatty acids into the bloodstream. Because high levels of circulating fatty acids are themselves a driver of insulin resistance in muscle and liver, reducing them improves how those organs handle glucose.³

Research in humans has confirmed that this mechanism works at the tissue level. Insulin-resistant people show abnormalities in skeletal muscle (including altered sugar metabolism and excess fat stored between muscle fibers) and in fat tissue (including poor mitochondrial function and increased inflammation). Glitazone treatment improved all of these abnormalities alongside the improvement in insulin sensitivity.⁴

More recently, researchers discovered that glitazones may also work through a second, completely separate mechanism: directly inhibiting a protein called the mitochondrial pyruvate carrier (MPC), which helps shuttle fuel into the cell’s energy-producing machinery. This inhibition happens at the drug concentrations people actually take, suggesting it may contribute meaningfully to the drugs’ effects on blood sugar.⁵ In liver cells specifically, pioglitazone suppressed glucose production in a way that appeared to depend on blocking pyruvate metabolism rather than just activating PPARγ.⁶ This dual mechanism may help explain why glitazones have such broad metabolic effects.

The Troubled History of the Class

Three glitazones have been marketed for diabetes. The story of each one has been shaped, to varying degrees, by safety problems.

Troglitazone (sold as Rezulin) was the first to reach patients, approved in the United States in 1997. Within a few years, reports of severe liver damage accumulated rapidly. Ninety-four cases of liver failure were eventually reported, and among the acute cases, only about one in eight recovered without needing a liver transplant. The drug was pulled from the U.S. market.⁷ The liver toxicity turned out to be specific to troglitazone’s chemical structure, not something shared by the other glitazones, but it cast a long shadow over the entire class.

Rosiglitazone (Avandia) took troglitazone’s place and quickly became one of the best-selling diabetes drugs in the world. Then, in 2007, a landmark meta-analysis found that rosiglitazone use was associated with roughly a 43% higher odds of heart attack compared to control groups.⁸ The finding triggered one of the most heated controversies in diabetes medicine. An updated analysis three years later, incorporating newer trials, still showed a statistically significant increase in heart attack risk, though it did not confirm a rise in cardiovascular death.⁹

The FDA placed severe restrictions on rosiglitazone in 2010, requiring a special prescriber program. Those restrictions were eventually lifted in 2013 after a re-evaluation, but the damage was done. Rosiglitazone’s share of diabetes prescriptions dropped below 1% and never recovered, even after the restrictions were removed. Pioglitazone’s market share also fell dramatically during this period, partly because of guilt-by-association with its sister drug and partly because new concerns emerged linking pioglitazone itself to a possible increase in bladder cancer risk.¹⁰

Side Effects That Limit Use

Even setting aside the headline-grabbing controversies, glitazones carry a distinctive side-effect profile that makes some doctors and patients hesitant. The most common issues are weight gain and fluid retention.

Weight gain occurs because the drugs actively promote the storage of fat in subcutaneous tissue (the fat under your skin). Pioglitazone treatment in one study led to an average gain of about 2.6 kilograms (roughly 5.7 pounds), along with a measurable shift of fat away from the abdominal organs and into subcutaneous stores.¹¹ A systematic review of randomized trials confirmed that glitazones consistently increase subcutaneous fat, total body fat, body weight, and waist circumference, while simultaneously reducing liver fat and visceral fat.¹² This paradox is key to understanding glitazones: you gain weight, but the fat gets redirected to metabolically safer locations, and insulin sensitivity improves. It is a hard sell for patients who equate any weight gain with a worsening condition, even though the metabolic picture is actually improving.

Fluid retention is a separate concern. Pioglitazone increases sodium reabsorption in the kidneys, leading to extra fluid in the body.¹³ For most people, this means some ankle swelling. But for someone with existing heart weakness, the extra fluid can tip them into congestive heart failure. This is the primary reason guidelines now discourage glitazones in patients with heart failure, and a major reason the class has been deprioritized more broadly.¹⁴

Bone health is a less obvious but well-documented concern. Activating PPARγ in bone marrow nudges stem cells toward becoming fat cells instead of bone-building cells. Over time, this shift reduces bone formation and can lead to bone loss.¹⁵ ¹⁶ The increased fracture risk appears more pronounced in women and tends to show up after prolonged use, making it an important consideration for long-term therapy.

The Bladder Cancer Question

The possibility that pioglitazone might increase bladder cancer risk has been one of the more persistent concerns surrounding the drug. The worry originated in animal studies, gained traction with a signal from a large clinical trial called PROactive, and was then supported by several observational studies suggesting a modestly elevated risk, particularly in people who used the drug for two or more years. These findings prompted regulators in some countries to issue warnings and in a few cases to suspend the drug’s marketing entirely.¹⁷

Meta-analyses pooling the available evidence have continued to evaluate this risk, often weighing it against the drug’s cardiovascular and liver benefits.¹⁸ The consensus at this point is cautious: pioglitazone is generally avoided in patients with active bladder cancer or a strong history of it, but for most other patients the absolute risk increase, if it is real, appears small relative to the drug’s metabolic benefits. In practice, this unresolved question has contributed to the overall chill around prescribing the class.

Where Pioglitazone Has Shown Surprising Strength

While glitazones have lost ground as first-line diabetes drugs, pioglitazone has been carving out a role in several conditions where its mechanism happens to be especially useful.

Stroke Prevention

Some of the most impressive evidence for pioglitazone lies outside diabetes treatment altogether. The IRIS trial, a major randomized study, enrolled nearly 3,900 patients who had recently suffered a stroke or transient ischemic attack and had insulin resistance but not diabetes. Over about five years, those given pioglitazone had a significantly lower rate of recurrent stroke or heart attack compared to placebo: roughly 9% experienced such an event, versus about 12% in the placebo group.¹⁹ An earlier trial specifically in diabetic patients with prior stroke found that pioglitazone cut the rate of fatal or nonfatal stroke roughly in half.²⁰

A systematic review combining these and other datasets confirmed the pattern: pioglitazone use in stroke patients with insulin resistance or diabetes was associated with about a 32% reduction in recurrent stroke and a 25% reduction in major vascular events.²¹ These numbers are large by the standards of stroke prevention, and they position pioglitazone as a serious option for a specific group of high-risk patients, something that diabetes guidelines have been slow to reflect.

Fatty Liver Disease

Non-alcoholic steatohepatitis (NASH), the inflammatory form of fatty liver disease, is one of the fastest-growing liver conditions worldwide, and treatment options are limited. Pioglitazone has emerged as one of the best-studied drugs for it, including in patients who do not have diabetes. A landmark trial found that pioglitazone significantly reduced liver fat, liver inflammation, and liver enzyme levels in NASH patients compared to placebo, though it did not improve fibrosis scores in that particular study.²²

However, a later meta-analysis of eight trials found that pioglitazone not only resolved NASH in many patients but also reversed advanced liver fibrosis, the scarring that drives progression to cirrhosis and liver failure. These benefits were observed in patients with and without diabetes.²³ A more recent systematic review of 15 randomized trials reinforced the conclusion that pioglitazone effectively improves liver function, blood sugar, and the severity of NASH itself.²⁴ Given how few drugs have shown this kind of liver benefit in rigorous trials, pioglitazone occupies a somewhat underappreciated position in liver medicine.

Polycystic Ovary Syndrome

Polycystic ovary syndrome (PCOS) involves insulin resistance, excess androgen hormones, and disrupted ovulation, all of which glitazones could plausibly address. Trials have tested pioglitazone in women with PCOS and found that it improved insulin sensitivity, lowered free androgen levels, and increased ovulation rates compared to placebo.²⁵ A comparative study found that pioglitazone restored ovulation in about 56% of treated patients over six months, slightly outperforming metformin at 44%, and produced more pronounced reductions in androgen levels.²⁶ Pioglitazone is not a standard first-line treatment for PCOS, partly because of the weight-gain issue in a population that often already struggles with weight, but the evidence for it is real and worth knowing about, particularly for women who don’t tolerate metformin well.

Why Your Genetics May Matter

Not everyone responds to glitazones the same way, and research into genetic variation helps explain why. A common variant in the PPARγ gene itself (known as Pro12Ala) has been linked to how well patients respond to pioglitazone. In one study of Chinese patients with type 2 diabetes, those carrying a specific version of this gene showed significantly greater improvements in blood sugar and triglyceride levels after three months of treatment.²⁷ The same Pro12Ala variant also appears to influence side effects: in a study of a related PPARγ drug, carriers of the more common version of the gene had roughly a fourfold higher risk of developing fluid retention and edema.²⁸ This kind of pharmacogenomic testing isn’t routine yet, but it hints at a future where prescribing could be tailored to each patient’s genetic profile.

The Weight-Gain Paradox in Practice

Of all the barriers to using pioglitazone, weight gain is probably the most underappreciated in its complexity. A study in type 2 diabetic patients confirmed the familiar pattern: pioglitazone significantly reduced fasting blood sugar, HbA1c, and triglyceride levels, but also caused significant weight gain.²⁹ In clinical practice, this is where many patients and physicians bail out. A drug that makes you heavier feels wrong for a condition associated with excess weight, even if the metabolic trade-off is favorable.

The nuance that often gets lost is that the weight gained on pioglitazone is not the same kind of weight that drives metabolic disease. The drug redirects fat away from the liver and abdominal organs, where it is most harmful, and into subcutaneous storage, where it is relatively benign. Liver fat specifically drops, and that drop correlates with improvements in insulin resistance and inflammation. For a patient whose primary risk is fatty liver disease or recurrent stroke, a few extra pounds of subcutaneous fat may be a worthwhile trade. But this is a hard argument to make to someone staring at a rising number on the scale, which is one reason clear communication about what the drug actually does to body composition matters.

The Failed Experiment With Dual-Acting Glitazars

Given glitazones’ clear metabolic benefits but also their limitations, pharmaceutical companies tried to build a better version. The idea was to combine PPARγ activation (which helps with blood sugar) with PPARα activation (which improves cholesterol and triglyceride levels) into a single drug. The resulting compounds, called glitazars, reached advanced clinical trials.³⁰

The metabolic data looked excellent: glitazars improved both blood sugar and lipid profiles better than either class alone. But one after another, they ran into heart-related safety problems. Muraglitazar, tesaglitazar, and aleglitazar were all abandoned during late-stage trials after they worsened heart failure in diabetic patients through mechanisms that researchers still do not fully understand.³¹ The pattern was striking: every metabolic marker improved, yet the hearts of patients got worse. This paradox has slowed enthusiasm for developing new PPAR-based drugs, though the idea of selectively activating parts of the PPAR pathway without triggering the harmful effects remains an active area of research.

Potential in Neurological Disease

Because PPARγ activation reduces inflammation broadly, researchers have explored whether pioglitazone might protect against neurodegenerative conditions like Parkinson’s disease. In a study of parkinsonian monkeys, pioglitazone reduced inflammatory cell activity in the brain in a dose-dependent manner.³² A comprehensive review of both animal and early human data concluded that pioglitazone consistently decreased brain inflammation, reduced oxidative stress, and improved motor and cognitive function across Parkinson’s disease models.³³ Whether these effects translate into meaningful clinical benefit in humans remains to be seen, but the rationale is biologically plausible and the preclinical results are encouraging enough to keep the research going. Similar lines of investigation exist for Alzheimer’s disease and multiple sclerosis, though the evidence is earlier-stage for those conditions.

The broader point is that glitazones are not just blood sugar drugs that happened to have side effects. They are powerful modulators of metabolism and inflammation whose reach extends into the liver, brain, cardiovascular system, and reproductive organs. The class’s troubled history has made the medical world cautious, but the growing evidence for pioglitazone in stroke prevention, fatty liver disease, and potentially neurological conditions suggests the story of these drugs is far from finished.